Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.54 |
| ▸ | ANPEP | P15144 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19805080 | 0.82 | PGR (0.74) | PGRANPEPALDH1A1KMT2APKM | |
| SCHEMBL787563 | 0.76 | PGR (0.50) | PGRANPEPALDH1A1KMT2APKM | |
| SCHEMBL2825967 | 0.75 | ANPEP (0.48) | ANPEPALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL2824816 | 0.72 | MAPT (0.44) | ANPEPALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL787719 | 0.71 | HDAC1 (0.39) | ANPEPALDH1A1HDAC1HDAC3HDAC8 | |
| SCHEMBL4847925 | 0.70 | PGR (1.00) | PGRALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL30642207 | 0.68 | ANPEP (0.49) | ANPEPALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL20616449 | 0.68 | PGR (0.49) | PGRALDH1A1 | |
| SCHEMBL26640052 | 0.68 | ANPEP (0.49) | ANPEPALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL26756233 | 0.68 | CUL4A (0.55) | ANPEPALDH1A1KMT2APKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-03-22 | — | — | US | claimed |
| WO-2010103064-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | WO | claimed |
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-03-22 | — | — | US | disclosed |
| WO-2010103064-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | PMP22, GRIN2C, NLN | PGR 3945/4885ANPEP 3708/4885ALDH1A1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.